Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 48 entries
Sorted by: Best Match Show Resources per page
Can Quantitative Muscle Strength and Functional Motor Ability Differentiate the Influence of Age and Corticosteroids in Ambulatory Boys with Duchenne Muscular Dystrophy?.

PLoS currents

Buckon C, Sienko S, Bagley A, Sison-Williamson M, Fowler E, Staudt L, Heberer K, McDonald CM, Sussman M.
PMID: 27500011
PLoS Curr. 2016 Jul 08;8. doi: 10.1371/currents.md.1ced64dff945f8958221fddcd4ee60b0.

BACKGROUND: In the absence of a curative treatment for Duchenne Muscular Dystrophy (DMD), corticosteroid therapy (prednisone, deflazacort) has been adopted as the standard of care, as it slows the progression of muscle weakness and enables longer retention of functional...

Cite
Buckon C, Sienko S, Bagley A, et al. Can Quantitative Muscle Strength and Functional Motor Ability Differentiate the Influence of Age and Corticosteroids in Ambulatory Boys with Duchenne Muscular Dystrophy?. PLoS Curr. 2016;8doi: 10.1371/currents.md.1ced64dff945f8958221fddcd4ee60b0.
Buckon, C., Sienko, S., Bagley, A., Sison-Williamson, M., Fowler, E., Staudt, L., Heberer, K., McDonald, C. M., & Sussman, M. (2016). Can Quantitative Muscle Strength and Functional Motor Ability Differentiate the Influence of Age and Corticosteroids in Ambulatory Boys with Duchenne Muscular Dystrophy?. PLoS currents, 8. https://doi.org/10.1371/currents.md.1ced64dff945f8958221fddcd4ee60b0
Buckon, Cathleen, et al. "Can Quantitative Muscle Strength and Functional Motor Ability Differentiate the Influence of Age and Corticosteroids in Ambulatory Boys with Duchenne Muscular Dystrophy?." PLoS currents vol. 8 (2016). doi: https://doi.org/10.1371/currents.md.1ced64dff945f8958221fddcd4ee60b0
Buckon C, Sienko S, Bagley A, Sison-Williamson M, Fowler E, Staudt L, Heberer K, McDonald CM, Sussman M. Can Quantitative Muscle Strength and Functional Motor Ability Differentiate the Influence of Age and Corticosteroids in Ambulatory Boys with Duchenne Muscular Dystrophy?. PLoS Curr. 2016 Jul 08;8. doi: 10.1371/currents.md.1ced64dff945f8958221fddcd4ee60b0. PMID: 27500011; PMCID: PMC4956479.
Copy Download .nbib Format: NLM
Corticosteroid-sparing effect of chromoglycate sodium and nedocromil.

Mediators of inflammation

Capristo AF, Del Giudice MM, Alfaro C, Maiello N.
PMID: 18475599
Mediators Inflamm. 1994;3(7):S25-30. doi: 10.1155/S0962935194000712.

The most appropiate management for bronchial asthma is the control of airway inflammation. Corticosteroids are the most effective anti-inflammatory drugs available, but they have a number of side effects; most of these are dose-dependent. In children, asthma control should...

Cite
Capristo AF, Del Giudice MM, Alfaro C, et al. Corticosteroid-sparing effect of chromoglycate sodium and nedocromil. Mediators Inflamm. 1994;3(7):S25-30doi: 10.1155/S0962935194000712.
Capristo, A. F., Del Giudice, M. M., Alfaro, C., & Maiello, N. (1994). Corticosteroid-sparing effect of chromoglycate sodium and nedocromil. Mediators of inflammation, 3(7), S25-30. https://doi.org/10.1155/S0962935194000712
Capristo, A F, et al. "Corticosteroid-sparing effect of chromoglycate sodium and nedocromil." Mediators of inflammation vol. 3,7 (1994): S25-30. doi: https://doi.org/10.1155/S0962935194000712
Capristo AF, Del Giudice MM, Alfaro C, Maiello N. Corticosteroid-sparing effect of chromoglycate sodium and nedocromil. Mediators Inflamm. 1994;3(7):S25-30. doi: 10.1155/S0962935194000712. PMID: 18475599; PMCID: PMC2365591.
Copy Download .nbib Format: NLM
In vitro cytochrome P450- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort-A major human metabolite of deflazacort.

Pharmacology research & perspectives

Ma J, Beers B, Manohar R, Roe S, Colacino JM, Kong R.
PMID: 33749127
Pharmacol Res Perspect. 2021 Apr;9(2):e00748. doi: 10.1002/prp2.748.

6β-Hydroxy-21-desacetyl deflazacort (6β-OH-21-desDFZ) is a major circulating but not biologically active metabolite of deflazacort (DFZ). In vitro studies were performed to evaluate cytochrome P450 (CYP)- and transporter-mediated drug interaction potentials of 6β-OH-21-desDFZ. Up to 50 µM, the highest soluble...

Cite
Ma J, Beers B, Manohar R, et al. In vitro cytochrome P450- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort-A major human metabolite of deflazacort. Pharmacol Res Perspect. 2021;9(2):e00748doi: 10.1002/prp2.748.
Ma, J., Beers, B., Manohar, R., Roe, S., Colacino, J. M., & Kong, R. (2021). In vitro cytochrome P450- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort-A major human metabolite of deflazacort. Pharmacology research & perspectives, 9(2), e00748. https://doi.org/10.1002/prp2.748
Ma, Jiyuan, et al. "In vitro cytochrome P450- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort-A major human metabolite of deflazacort." Pharmacology research & perspectives vol. 9,2 (2021): e00748. doi: https://doi.org/10.1002/prp2.748
Ma J, Beers B, Manohar R, Roe S, Colacino JM, Kong R. In vitro cytochrome P450- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort-A major human metabolite of deflazacort. Pharmacol Res Perspect. 2021 Apr;9(2):e00748. doi: 10.1002/prp2.748. PMID: 33749127; PMCID: PMC7982320.
Copy Download .nbib Format: NLM
Influence of Different Types of Corticosteroids on Heart Rate Variability of Individuals with Duchenne Muscular Dystrophy-A Pilot Cross Sectional Study.

Life (Basel, Switzerland)

Dias RM, Hoshi RA, Vanderlei LCM, Monteiro CBM, Alvarez MPB, Crocetta TB, Grossklauss LF, Fernani DCGL, Dantas MTAP, Martins FPA, Garner DM, Abreu LC, Ferreira C, da Silva TD.
PMID: 34440496
Life (Basel). 2021 Jul 27;11(8). doi: 10.3390/life11080752.

Individuals with Duchenne Muscular Dystrophy (DMD) have an impairment of cardiac autonomic function categorized by parasympathetic reduction and sympathetic predominance. The objective of this study was to assess the cardiac autonomic modulation of individuals with DMD undergoing therapy with...

Cite
Dias RM, Hoshi RA, Vanderlei LCM, et al. Influence of Different Types of Corticosteroids on Heart Rate Variability of Individuals with Duchenne Muscular Dystrophy-A Pilot Cross Sectional Study. Life (Basel). 2021;11(8)doi: 10.3390/life11080752.
Dias, R. M., Hoshi, R. A., Vanderlei, L. C. M., Monteiro, C. B. M., Alvarez, M. P. B., Crocetta, T. B., Grossklauss, L. F., Fernani, D. C. G. L., Dantas, M. T. A. P., Martins, F. P. A., Garner, D. M., Abreu, L. C., Ferreira, C., & da Silva, T. D. (2021). Influence of Different Types of Corticosteroids on Heart Rate Variability of Individuals with Duchenne Muscular Dystrophy-A Pilot Cross Sectional Study. Life (Basel, Switzerland), 11(8), . https://doi.org/10.3390/life11080752
Dias, Rodrigo Martins, et al. "Influence of Different Types of Corticosteroids on Heart Rate Variability of Individuals with Duchenne Muscular Dystrophy-A Pilot Cross Sectional Study." Life (Basel, Switzerland) vol. 11,8 (2021). doi: https://doi.org/10.3390/life11080752
Dias RM, Hoshi RA, Vanderlei LCM, Monteiro CBM, Alvarez MPB, Crocetta TB, Grossklauss LF, Fernani DCGL, Dantas MTAP, Martins FPA, Garner DM, Abreu LC, Ferreira C, da Silva TD. Influence of Different Types of Corticosteroids on Heart Rate Variability of Individuals with Duchenne Muscular Dystrophy-A Pilot Cross Sectional Study. Life (Basel). 2021 Jul 27;11(8). doi: 10.3390/life11080752. PMID: 34440496; PMCID: PMC8398672.
Copy Download .nbib Format: NLM
Systemic corticosteroids for management of 'long-COVID': an evaluation after 3 months of treatment.

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace

Goel N, Goyal N, Nagaraja R, Kumar R.
PMID: 34730322
Monaldi Arch Chest Dis. 2021 Nov 03; doi: 10.4081/monaldi.2021.1981. Epub 2021 Nov 03.

Some patients even 4 weeks after Corona Virus Disease 2019 (COVID-19) remain to be symptomatic and are known as "long-COVID". In the present study we performed the follow up evaluation at 3 months of long-COVID patients, after treatment with...

Cite
Goel N, Goyal N, Nagaraja R, et al. Systemic corticosteroids for management of 'long-COVID': an evaluation after 3 months of treatment. Monaldi Arch Chest Dis. 2021;doi: 10.4081/monaldi.2021.1981.
Goel, N., Goyal, N., Nagaraja, R., & Kumar, R. (2021). Systemic corticosteroids for management of 'long-COVID': an evaluation after 3 months of treatment. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, . https://doi.org/10.4081/monaldi.2021.1981
Goel, Nitin, et al. "Systemic corticosteroids for management of 'long-COVID': an evaluation after 3 months of treatment." Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace vol. (2021). doi: https://doi.org/10.4081/monaldi.2021.1981
Goel N, Goyal N, Nagaraja R, Kumar R. Systemic corticosteroids for management of 'long-COVID': an evaluation after 3 months of treatment. Monaldi Arch Chest Dis. 2021 Nov 03; doi: 10.4081/monaldi.2021.1981. Epub 2021 Nov 03. PMID: 34730322.
Copy Download .nbib Format: NLM
Retrospective cohort study comparing the efficacy of prednisolone and deflazacort in children with muscular dystrophy: A 6 years' experience in a South Indian teaching hospital.

Indian journal of orthopaedics

Petnikota H, Madhuri V, Gangadharan S, Agarwal I, Antonisamy B.
PMID: 27746500
Indian J Orthop. 2016 Sep;50(5):551-557. doi: 10.4103/0019-5413.189609.

BACKGROUND: Muscular dystrophies are inherited myogenic disorders characterized by progressive muscle wasting and weakness of variable distribution and severity. They are a heterogeneous group characterized by variable degree of skeletal and cardiac muscle involvement. The most common and the...

Cite
Petnikota H, Madhuri V, Gangadharan S, et al. Retrospective cohort study comparing the efficacy of prednisolone and deflazacort in children with muscular dystrophy: A 6 years' experience in a South Indian teaching hospital. Indian J Orthop. 2016;50(5):551-557doi: 10.4103/0019-5413.189609.
Petnikota, H., Madhuri, V., Gangadharan, S., Agarwal, I., & Antonisamy, B. (2016). Retrospective cohort study comparing the efficacy of prednisolone and deflazacort in children with muscular dystrophy: A 6 years' experience in a South Indian teaching hospital. Indian journal of orthopaedics, 50(5), 551-557. https://doi.org/10.4103/0019-5413.189609
Petnikota, Harish, et al. "Retrospective cohort study comparing the efficacy of prednisolone and deflazacort in children with muscular dystrophy: A 6 years' experience in a South Indian teaching hospital." Indian journal of orthopaedics vol. 50,5 (2016): 551-557. doi: https://doi.org/10.4103/0019-5413.189609
Petnikota H, Madhuri V, Gangadharan S, Agarwal I, Antonisamy B. Retrospective cohort study comparing the efficacy of prednisolone and deflazacort in children with muscular dystrophy: A 6 years' experience in a South Indian teaching hospital. Indian J Orthop. 2016 Sep;50(5):551-557. doi: 10.4103/0019-5413.189609. PMID: 27746500; PMCID: PMC5017179.
Copy Download .nbib Format: NLM
Online self-report data for duchenne muscular dystrophy confirms natural history and can be used to assess for therapeutic benefits.

PLoS currents

Wang RT, Silverstein Fadlon CA, Ulm JW, Jankovic I, Eskin A, Lu A, Rangel Miller V, Cantor RM, Li N, Elashoff R, Martin AS, Peay HL, Halnon N, Nelson SF.
PMID: 25635234
PLoS Curr. 2014 Oct 17;6. doi: 10.1371/currents.md.e1e8f2be7c949f9ffe81ec6fca1cce6a.

To assess the utility of online patient self-report outcomes in a rare disease, we attempted to observe the effects of corticosteroids in delaying age at fulltime wheelchair use in Duchenne muscular dystrophy (DMD) using data from 1,057 males from...

Cite
Wang RT, Silverstein Fadlon CA, Ulm JW, et al. Online self-report data for duchenne muscular dystrophy confirms natural history and can be used to assess for therapeutic benefits. PLoS Curr. 2014;6doi: 10.1371/currents.md.e1e8f2be7c949f9ffe81ec6fca1cce6a.
Wang, R. T., Silverstein Fadlon, C. A., Ulm, J. W., Jankovic, I., Eskin, A., Lu, A., Rangel Miller, V., Cantor, R. M., Li, N., Elashoff, R., Martin, A. S., Peay, H. L., Halnon, N., & Nelson, S. F. (2014). Online self-report data for duchenne muscular dystrophy confirms natural history and can be used to assess for therapeutic benefits. PLoS currents, 6. https://doi.org/10.1371/currents.md.e1e8f2be7c949f9ffe81ec6fca1cce6a
Wang, Richard T, et al. "Online self-report data for duchenne muscular dystrophy confirms natural history and can be used to assess for therapeutic benefits." PLoS currents vol. 6 (2014). doi: https://doi.org/10.1371/currents.md.e1e8f2be7c949f9ffe81ec6fca1cce6a
Wang RT, Silverstein Fadlon CA, Ulm JW, Jankovic I, Eskin A, Lu A, Rangel Miller V, Cantor RM, Li N, Elashoff R, Martin AS, Peay HL, Halnon N, Nelson SF. Online self-report data for duchenne muscular dystrophy confirms natural history and can be used to assess for therapeutic benefits. PLoS Curr. 2014 Oct 17;6. doi: 10.1371/currents.md.e1e8f2be7c949f9ffe81ec6fca1cce6a. PMID: 25635234; PMCID: PMC4207635.
Copy Download .nbib Format: NLM
PYED-1 Inhibits Biofilm Formation and Disrupts the Preformed Biofilm of .

Antibiotics (Basel, Switzerland)

Vollaro A, Esposito A, Esposito EP, Zarrilli R, Guaragna A, De Gregorio E.
PMID: 32397205
Antibiotics (Basel). 2020 May 08;9(5). doi: 10.3390/antibiotics9050240.

Pregnadiene-11-hydroxy-16α,17α-epoxy-3,20-dione-1 (PYED-1), a heterocyclic corticosteroid derivative of deflazacort, exhibits broad-spectrum antibacterial activity against Gram-negative and Gram-positive bacteria. Here, we investigated the effect of PYED-1 on the biofilms of

Cite
Vollaro A, Esposito A, Esposito EP, et al. PYED-1 Inhibits Biofilm Formation and Disrupts the Preformed Biofilm of . Antibiotics (Basel). 2020;9(5)doi: 10.3390/antibiotics9050240.
Vollaro, A., Esposito, A., Esposito, E. P., Zarrilli, R., Guaragna, A., & De Gregorio, E. (2020). PYED-1 Inhibits Biofilm Formation and Disrupts the Preformed Biofilm of . Antibiotics (Basel, Switzerland), 9(5), . https://doi.org/10.3390/antibiotics9050240
Vollaro, Adriana, et al. "PYED-1 Inhibits Biofilm Formation and Disrupts the Preformed Biofilm of ." Antibiotics (Basel, Switzerland) vol. 9,5 (2020). doi: https://doi.org/10.3390/antibiotics9050240
Vollaro A, Esposito A, Esposito EP, Zarrilli R, Guaragna A, De Gregorio E. PYED-1 Inhibits Biofilm Formation and Disrupts the Preformed Biofilm of . Antibiotics (Basel). 2020 May 08;9(5). doi: 10.3390/antibiotics9050240. PMID: 32397205; PMCID: PMC7277567.
Copy Download .nbib Format: NLM
Deflazacort-induced Acneiform Eruptions.

Journal of pharmacy & bioallied sciences

Bashir MSM, Saleem M, Choudhari U.
PMID: 29456382
J Pharm Bioallied Sci. 2017 Oct-Dec;9(4):284-286. doi: 10.4103/jpbs.JPBS_67_17.

A 38-year-old male suffering from a low backache since 3 months was diagnosed as a case of L4-L5 disc prolapse after magnetic resonance imaging examination. He was treated with tolperisone, aceclofenac, and paracetamol in these drugs deflazacort added later....

Cite
Bashir MSM, Saleem M, Choudhari U. Deflazacort-induced Acneiform Eruptions. J Pharm Bioallied Sci. 2017;9(4):284-286doi: 10.4103/jpbs.JPBS_67_17.
Bashir, M. S. M., Saleem, M., & Choudhari, U. (2017). Deflazacort-induced Acneiform Eruptions. Journal of pharmacy & bioallied sciences, 9(4), 284-286. https://doi.org/10.4103/jpbs.JPBS_67_17
Bashir, Mohammed Shakeel Mohammed, et al. "Deflazacort-induced Acneiform Eruptions." Journal of pharmacy & bioallied sciences vol. 9,4 (2017): 284-286. doi: https://doi.org/10.4103/jpbs.JPBS_67_17
Bashir MSM, Saleem M, Choudhari U. Deflazacort-induced Acneiform Eruptions. J Pharm Bioallied Sci. 2017 Oct-Dec;9(4):284-286. doi: 10.4103/jpbs.JPBS_67_17. PMID: 29456382; PMCID: PMC5810081.
Copy Download .nbib Format: NLM
Head to head comparison of adverse effects and efficacy between high dose deflazacort and high dose prednisolone in systemic lupus erythematosus: a prospective cohort study.

Lupus

Ganapati A, Ravindran R, David T, Yadav B, Jeyaseelan V, Jeyaseelan L, Danda D.
PMID: 29320974
Lupus. 2018 May;27(6):890-898. doi: 10.1177/0961203317751854. Epub 2018 Jan 10.

BACKGROUND: Deflazacort (DFZ), an oxazoline derivative of prednisolone (PDN), has a dose equivalence of 1.2:1 (mg) to PDN. No study to date has compared adverse effects and efficacy of high doses of DFZ as against high-dose PDN in systemic...

Cite
Ganapati A, Ravindran R, David T, et al. Head to head comparison of adverse effects and efficacy between high dose deflazacort and high dose prednisolone in systemic lupus erythematosus: a prospective cohort study. Lupus. 2018;27(6):890-898doi: 10.1177/0961203317751854.
Ganapati, A., Ravindran, R., David, T., Yadav, B., Jeyaseelan, V., Jeyaseelan, L., & Danda, D. (2018). Head to head comparison of adverse effects and efficacy between high dose deflazacort and high dose prednisolone in systemic lupus erythematosus: a prospective cohort study. Lupus, 27(6), 890-898. https://doi.org/10.1177/0961203317751854
Ganapati, A, et al. "Head to head comparison of adverse effects and efficacy between high dose deflazacort and high dose prednisolone in systemic lupus erythematosus: a prospective cohort study." Lupus vol. 27,6 (2018): 890-898. doi: https://doi.org/10.1177/0961203317751854
Ganapati A, Ravindran R, David T, Yadav B, Jeyaseelan V, Jeyaseelan L, Danda D. Head to head comparison of adverse effects and efficacy between high dose deflazacort and high dose prednisolone in systemic lupus erythematosus: a prospective cohort study. Lupus. 2018 May;27(6):890-898. doi: 10.1177/0961203317751854. Epub 2018 Jan 10. PMID: 29320974.
Copy Download .nbib Format: NLM
Interferon-alpha-n1: a review of its pharmacological properties and therapeutic efficacy in the management of chronic viral hepatitis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Perry CM, Wagstaff AJ.
PMID: 18020550
BioDrugs. 1998 Feb;9(2):125-54. doi: 10.2165/00063030-199809020-00004.

Interferon-alpha-n1 (lymphoblastoid interferon-alpha) is a nonrecombinant 'natural' interferon derived from lymphoblastoid cells exposed to Sendai virus. In common with endogenous and recombinant interferon-alpha molecules, interferon-alpha-n1 has antiviral, immunomodulatory and antiproliferative properties. Interferon-alpha-n1 shows some efficacy in immunocompetent adults with...

Cite
Perry CM, Wagstaff AJ. Interferon-alpha-n1: a review of its pharmacological properties and therapeutic efficacy in the management of chronic viral hepatitis. BioDrugs. 1998;9(2):125-54doi: 10.2165/00063030-199809020-00004.
Perry, C. M., & Wagstaff, A. J. (1998). Interferon-alpha-n1: a review of its pharmacological properties and therapeutic efficacy in the management of chronic viral hepatitis. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 9(2), 125-54. https://doi.org/10.2165/00063030-199809020-00004
Perry, C M, and Wagstaff, A J. "Interferon-alpha-n1: a review of its pharmacological properties and therapeutic efficacy in the management of chronic viral hepatitis." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 9,2 (1998): 125-54. doi: https://doi.org/10.2165/00063030-199809020-00004
Perry CM, Wagstaff AJ. Interferon-alpha-n1: a review of its pharmacological properties and therapeutic efficacy in the management of chronic viral hepatitis. BioDrugs. 1998 Feb;9(2):125-54. doi: 10.2165/00063030-199809020-00004. PMID: 18020550.
Copy Download .nbib Format: NLM
Deflazacort approved for Duchenne muscular dystrophy.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Traynor K.
PMID: 28274975
Am J Health Syst Pharm. 2017 Mar 15;74(6):368. doi: 10.2146/news170020.

No abstract available.

Cite
Traynor K. Deflazacort approved for Duchenne muscular dystrophy. Am J Health Syst Pharm. 2017;74(6):368doi: 10.2146/news170020.
Traynor, K. (2017). Deflazacort approved for Duchenne muscular dystrophy. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 74(6), 368. https://doi.org/10.2146/news170020
Traynor, Kate. "Deflazacort approved for Duchenne muscular dystrophy." American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists vol. 74,6 (2017): 368. doi: https://doi.org/10.2146/news170020
Traynor K. Deflazacort approved for Duchenne muscular dystrophy. Am J Health Syst Pharm. 2017 Mar 15;74(6):368. doi: 10.2146/news170020. PMID: 28274975.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 48 entries